Dose Optimization of Inotuzumab Ozogamicin in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

被引：0
|
作者：
Deangelo, Daniel J. [1 ]
Chen, Ying [2 ]
Cassaday, Ryan D. [3 ,4 ]
Hibma, Jennifer [2 ]
Yang, Derek Z. [2 ]
Garrett, May [2 ]
Zhang, Fan [5 ]
Dimitrov, Svetoslav H. [6 ]
Vandendries, Erik [7 ]
Kantarjian, Hagop M. [8 ]
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[2] Pfizer, San Diego, CA USA
[3] Univ Washington, Seattle, WA USA
[4] Fred Hutchinson Canc Ctr, Seattle, WA USA
[5] Pfizer, Shanghai, Peoples R China
[6] Pfizer, New York, NY USA
[7] Pfizer Inc, Cambridge, MA USA
[8] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-194244
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：732 / 733
页数：2
相关论文
共 50 条
  • [21] Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin
    Paul, Shilpa
    Rausch, Caitlin R.
    Kantarjian, Hagop
    Jabbour, Elias J.
    FUTURE ONCOLOGY, 2017, 13 (25) : 2233 - 2242
  • [22] Inotuzumab Ozogamicin for Patients with relapsed or refractory acute Lymphoblastic Leukemia: Effective Option also in Patients with extramedullary Disease
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (03) : 142 - 142
  • [23] Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
    Irina Proskorovsky
    Yun Su
    Kyle Fahrbach
    Erik Vandendries
    Véronique Pagé
    Uchenna Onyekwere
    Yunyang Wang
    Joseph C. Cappelleri
    Matthias Stelljes
    Advances in Therapy, 2019, 36 : 2147 - 2160
  • [24] Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
    Proskorovsky, Irina
    Su, Yun
    Fahrbach, Kyle
    Vandendries, Erik
    Page, Veronique
    Onyekwere, Uchenna
    Wang, Yunyang
    Cappelleri, Joseph C.
    Stelljes, Matthias
    ADVANCES IN THERAPY, 2019, 36 (08) : 2147 - 2160
  • [25] Outcome of Relapsed or Refractory Acute B-Lymphoblastic Leukemia Patients with Extramedullary Disease Receiving Inotuzumab Ozogamicin
    Kayser, Sabine
    Sartor, Chiara
    Panitz, Nydia
    Fante, Matthias
    Lutz, Christoph
    Wolff, Daniel
    Ho, Anthony
    Papayannidis, Cristina
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S265 - S265
  • [26] Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia
    Thota, Swapna
    Advani, Anjali
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 98 (05) : 425 - 434
  • [27] Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma
    Garrett, May
    Ruiz-Garcia, Ana
    Parivar, Kourosh
    Hee, Brian
    Boni, Joseph
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2019, 46 (03) : 211 - 222
  • [28] A Retrospective Study on Inotuzumab Ozogamicin in Infants and Young Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
    Brivio, Erica
    Hoogendijk, Raoull
    Chantrain, Christophe
    Rialland, Fanny
    Contet, Audrey
    Elitzur, Sarah
    Dalla-Pozza, Luciano
    Kallay, Krisztian
    Li, Chi Kong
    Kato, Motohiro
    Markova, Inna V.
    Schmiegelow, Kjeld
    Bodmer, Nicole
    Pieters, Rob
    Zwaan, Christian Michel
    BLOOD, 2019, 134
  • [29] BUDGET IMPACT ANALYSIS OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA IN ALGERIA
    Djemai, S.
    Derki, S.
    Enzrati, Jalal J.
    Russell-Smith, T. A.
    VALUE IN HEALTH, 2024, 27 (12) : S83 - S84
  • [30] The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia
    Yilmaz, Musa
    Richard, Samantha
    Jabbour, Elias
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2015, 6 (05) : 253 - 261
12345